The White House moved to accelerate federal handling of psychedelic drugs, including ibogaine, while leaving core approval, scheduling and reimbursement hurdles in place. President Donald Trump on April 18 signed an executive order directing federal agencies to speed review, research, and access pathways for psychedelic drugs, with a focus on serious mental illness and veteran […]
The post Whitehouse Directs FDA, HHS and VA to Expand Psychedelic Research Pathways appeared first on Psychedelics Today.
